Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128693) titled 'A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Zhengzhou University
Condition:
Esophageal Squamous Cell Carcinoma
Intervention:
Drug: Sacituzumab Tirumotecan in combination with tislelizumab
Recruitment Status:...